Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Wennen aan de Europese regels voor geneesmiddelenonderzoek
apr 2024